Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    18222192 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Treat and Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Condition: Macular Degeneration
Intervention: Drug: 0.5mg ranibizumab
2 Recruiting Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
Condition: Radiation Retinopathy
Interventions: Drug: 0.5 mg ranibizumab;   Procedure: Targeted Retinal Photocoagulation
3 Completed The Effect of Ranibizumab on Eye Lens Opacity in Cases With Age-Related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Cataract
Intervention:
4 Completed A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)

Indicates status has not been verified in more than two years